is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
CPhI Middle East & Africa 2019, the global pharmaceutical showcase held in Abu Dhabi, has concluded after welcoming 234 exhibiting companies and over 3,100 visitors, from 98 countries. His Excellency Sheikh Nahyan bin Mubarak al Nahyan, Minister of Tolerance, opened the event on 16 September, amid the projected US$41 billion the pharmaceutical industry in the MENA region is expected to top by 2022.
Abu Dhabi, United Arab Emirates, 18 September 2019: CPhI Middle East & Africa concluded today at the Abu Dhabi National Exhibition Centre (ADNEC) with a panel discussion addressing the UAEs commitment to becoming an innovative market while effectively managing healthcare spending in the region.
CPhI pharma event hosts discussion on how Saudi Arabia pharmaceutical industry is helping to deliver the country’s Vision 2030. The Saudi pharma market is the largest across the MENA region with a market size of US$7.5 billion with a growth expected at a CAGR of around 5.5% according to experts.
His Excellency Sheikh Nahyan bin Mubarak al Nahyan, Minister of Tolerance, inaugurates CPhI Middle East & Africa 2018. Global industry professionals descend upon ADNEC in Abu Dhabi for the region’s leading platform for the pharmaceutical sector.
The event, which is returning for a second year after its successful launch in the capital last year, will take place at the Abu Dhabi National Exhibition Centre (ADNEC) from 16-18 September 2019. Sponsored by the Ministry of Health and Protection (MoHaP), CPhI is set to attract attendees from the Middle East and Africa (MEA) - of which the MENA region accounts for 4% of the global pharma market - and the rest of the world.
Saudi Arabia’s pharmaceutical market expected to grow at a CAGR of 5.5% until 2023. Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.